These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24054336)

  • 1. Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure.
    Shao Z; Shrestha K; Borowski AG; Kennedy DJ; Epelman S; Thomas JD; Tang WH
    J Card Fail; 2013 Sep; 19(9):605-10. PubMed ID: 24054336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure.
    Úri K; Fagyas M; Mányiné Siket I; Kertész A; Csanádi Z; Sándorfi G; Clemens M; Fedor R; Papp Z; Édes I; Tóth A; Lizanecz E
    PLoS One; 2014; 9(4):e87845. PubMed ID: 24691269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes.
    Epelman S; Shrestha K; Troughton RW; Francis GS; Sen S; Klein AL; Tang WH
    J Card Fail; 2009 Sep; 15(7):565-71. PubMed ID: 19700132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study.
    Ortiz-Pérez JT; Riera M; Bosch X; De Caralt TM; Perea RJ; Pascual J; Soler MJ
    PLoS One; 2013; 8(4):e61695. PubMed ID: 23630610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system.
    Epelman S; Tang WH; Chen SY; Van Lente F; Francis GS; Sen S
    J Am Coll Cardiol; 2008 Aug; 52(9):750-4. PubMed ID: 18718423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value.
    Almengló C; Couselo-Seijas M; Agra RM; Varela-Román A; García-Acuña JM; González-Peteiro M; González-Juanatey JR; Eiras S; Álvarez E
    J Mol Med (Berl); 2021 Dec; 99(12):1741-1753. PubMed ID: 34529122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble angiotensin converting enzyme 2 levels in chronic heart failure is associated with decreased exercise capacity and increased oxidative stress-mediated endothelial dysfunction.
    Shao Z; Schuster A; Borowski AG; Thakur A; Li L; Wilson Tang WH
    Transl Res; 2019 Oct; 212():80-88. PubMed ID: 31323221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers.
    Lundström A; Ziegler L; Havervall S; Rudberg AS; von Meijenfeldt F; Lisman T; Mackman N; Sandén P; Thålin C
    J Med Virol; 2021 Oct; 93(10):5908-5916. PubMed ID: 34138483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.
    Wallentin L; Lindbäck J; Eriksson N; Hijazi Z; Eikelboom JW; Ezekowitz MD; Granger CB; Lopes RD; Yusuf S; Oldgren J; Siegbahn A
    Eur Heart J; 2020 Nov; 41(41):4037-4046. PubMed ID: 32984892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study).
    Hussain A; Tang O; Sun C; Jia X; Selvin E; Nambi V; Folsom A; Heiss G; Zannad F; Mosley T; Virani SS; Coresh J; Boerwinkle E; Yu B; Cunningham JW; Shah AM; Solomon SD; de Lemos JA; Hoogeveen RC; Ballantyne CM
    Am J Cardiol; 2021 May; 146():15-21. PubMed ID: 33539861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictability of renin-angiotensin-aldosterone system factors for clinical outcome in patients with acute decompensated heart failure.
    Nakada Y; Takahama H; Kanzaki H; Sugano Y; Hasegawa T; Ohara T; Amaki M; Funada A; Yoshida A; Yasuda S; Ogawa H; Anzai T
    Heart Vessels; 2016 Jun; 31(6):925-31. PubMed ID: 25964073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of soluble angiotensin-converting enzyme 2 concentrations in adult patients with complex congenital heart disease.
    Raedle-Hurst T; Wissing S; Mackenstein N; Obeid R; Geisel J; Wagenpfeil S; Abdul-Khaliq H
    Clin Res Cardiol; 2022 Feb; 111(2):154-162. PubMed ID: 33280062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Right ventricular response to intensive medical therapy in advanced decompensated heart failure.
    Verhaert D; Mullens W; Borowski A; Popović ZB; Curtin RJ; Thomas JD; Tang WH
    Circ Heart Fail; 2010 May; 3(3):340-6. PubMed ID: 20176715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure.
    Chirinos JA; Cohen JB; Zhao L; Hanff T; Sweitzer N; Fang J; Corrales-Medina V; Anmar R; Morley M; Zamani P; Bhattacharya P; Brandimarto J; Jia Y; Basso MD; Wang Z; Ebert C; Ramirez-Valle F; Schafer PH; Seiffert D; Gordon DA; Cappola T
    Hypertension; 2020 Nov; 76(5):1526-1536. PubMed ID: 32981365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease.
    Ramchand J; Patel SK; Srivastava PM; Farouque O; Burrell LM
    PLoS One; 2018; 13(6):e0198144. PubMed ID: 29897923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The serum angiotensin-converting enzyme 2 and angiotensin-(1-7) concentrations after optimal therapy for acute decompensated heart failure with reduced ejection fraction.
    Hisatake S; Kiuchi S; Kabuki T; Oka T; Dobashi S; Fujii T; Ikeda T
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32458985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain natriuretic peptide levels have diagnostic and prognostic capability for cardio-renal syndrome type 4 in intensive care unit patients.
    Park S; Cho GY; Kim SG; Hwang YI; Kang HR; Jang SH; Kim DG; Song YR; Bae YA; Jung KS
    Crit Care; 2009; 13(3):R70. PubMed ID: 19445682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease.
    Roberts MA; Velkoska E; Ierino FL; Burrell LM
    Nephrol Dial Transplant; 2013 Sep; 28(9):2287-94. PubMed ID: 23535224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of serial increases in amino-terminal pro-B-type natriuretic peptide levels to indicate the need for mechanical circulatory support in children with acute decompensated heart failure.
    Wong DT; George K; Wilson J; Manlhiot C; McCrindle BW; Adeli K; Kantor PF
    Am J Cardiol; 2011 Feb; 107(4):573-8. PubMed ID: 21295174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both.
    Yan RT; White M; Yan AT; Yusuf S; Rouleau JL; Maggioni AP; Hall C; Latini R; Afzal R; Floras J; Masson S; McKelvie RS;
    Am J Cardiol; 2005 Sep; 96(5):698-704. PubMed ID: 16125499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.